Medical AI company AIDOT announced on the 24th that it has signed a lead-manager agreement with Korea Investment & Securities to pursue a KOSDAQ listing.
AIDOT has developed and completed the world’s first AI cervical cancer diagnostic system, “Cerviray,” as well as “SonoDot AI,” a carotid diagnostic system for stroke prevention, and is moving forward with commercialization efforts.
The company is also building a robust pipeline that includes a microbiome-based diagnostic system for alcoholic liver disease and an AI-based diagnostic system covering all areas of gastroenterology.
CEO Jeong Jae-hoon said, “Based on the approvals we have prepared and our unmatched technological capabilities, we are pursuing a KOSDAQ listing grounded in global revenue performance,” adding, “Rather than a one-off supply of AI medical solutions, the company has built and completed a business model that generates ongoing screening revenue, and we are ahead of global competitors with similar models in places such as Israel.”
He added, “This lead-manager agreement with Korea Investment & Securities for a KOSDAQ listing goes beyond Series A funding—it was made possible on the foundation of thorough business and technology validation for AIDOT’s leap into a global company,” and said, “We will devote all our efforts to forging a new path in showing how AI medical solutions can generate revenue and maximize profit.”
Published: September 24, 2021 / Korea Economic TV
